JP2009524419A - Ｌｎａ修飾したホスホロチオール化オリゴヌクレオチド - Google Patents

Ｌｎａ修飾したホスホロチオール化オリゴヌクレオチド Download PDF

Info

Publication number
JP2009524419A
JP2009524419A JP2008551732A JP2008551732A JP2009524419A JP 2009524419 A JP2009524419 A JP 2009524419A JP 2008551732 A JP2008551732 A JP 2008551732A JP 2008551732 A JP2008551732 A JP 2008551732A JP 2009524419 A JP2009524419 A JP 2009524419A
Authority
JP
Japan
Prior art keywords
lna
oligonucleotide
mixed sequence
rna
sequence oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008551732A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009524419A5 (enExample
Inventor
ヨアヒム・エルメン
ヘンリク・フリゼンルン・ハンセン
ヘンリク・エルム
トレルス・コッホ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Innovation Center Copenhagen AS
Original Assignee
Santaris Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santaris Pharma AS filed Critical Santaris Pharma AS
Publication of JP2009524419A publication Critical patent/JP2009524419A/ja
Publication of JP2009524419A5 publication Critical patent/JP2009524419A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
JP2008551732A 2006-01-27 2007-01-29 Ｌｎａ修飾したホスホロチオール化オリゴヌクレオチド Pending JP2009524419A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76292006P 2006-01-27 2006-01-27
PCT/EP2007/000741 WO2007085485A2 (en) 2006-01-27 2007-01-29 Lna modified phosphorothiolated oligonucleotides

Publications (2)

Publication Number Publication Date
JP2009524419A true JP2009524419A (ja) 2009-07-02
JP2009524419A5 JP2009524419A5 (enExample) 2010-03-11

Family

ID=38007090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008551732A Pending JP2009524419A (ja) 2006-01-27 2007-01-29 Ｌｎａ修飾したホスホロチオール化オリゴヌクレオチド

Country Status (7)

Country Link
US (1) US20090176977A1 (enExample)
EP (1) EP1984382B1 (enExample)
JP (1) JP2009524419A (enExample)
AU (1) AU2007209481B2 (enExample)
CA (1) CA2638837A1 (enExample)
DK (1) DK1984382T3 (enExample)
WO (1) WO2007085485A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018504380A (ja) * 2014-12-18 2018-02-15 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｒｅｖｅｒｓｉｒ（商標）化合物

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1606406B2 (en) 2003-03-21 2013-11-27 Santaris Pharma A/S SHORT INTERFERING RNA (siRNA) ANALOGUES
DK1713912T3 (da) * 2004-01-30 2013-12-16 Santaris Pharma As Modificerede Korte Interfererende RNA (Modificerede siRNA)
DK2002004T3 (en) 2006-03-23 2015-11-30 Roche Innovation Ct Copenhagen As LITTLE INTERNAL SEGMENTED INTERFERENCE RNA
DK2195428T3 (en) 2007-09-19 2014-03-03 Applied Biosystems Llc SIRNA SEQUENCE-INDEPENDENT MODIFICATION FORMS TO REDUCE TARGET-FAILING PHENOTYPIC EFFECTS OF RNAI, AND STABILIZED FORMS THEREOF
JP2010539961A (ja) * 2007-10-04 2010-12-24 サンタリス ファーマ アー／エス ＨＩＦ１αの調節のための短いＲＮＡアンタゴニスト化合物
US20120046236A1 (en) * 2009-05-06 2012-02-23 Opko Curna Llc Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
US20150025122A1 (en) 2009-10-12 2015-01-22 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
WO2011108930A1 (en) 2010-03-04 2011-09-09 Interna Technologies Bv A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT
EP2591106A1 (en) 2010-07-06 2013-05-15 InteRNA Technologies B.V. Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
EP2776566A1 (en) * 2011-11-11 2014-09-17 Santaris Pharma A/S Compounds for the modulation of beta-catenin expression and uses thereof
WO2013095132A1 (en) 2011-12-22 2013-06-27 Interna Technologies B.V. Mirna for treating head and neck cancer
WO2014072357A1 (en) 2012-11-06 2014-05-15 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
RU2015119411A (ru) 2012-11-15 2017-01-10 Рош Инновейшен Сентер Копенгаген А/С Конъюгаты антисмысловых соединений, направленные на аполипопротеин в
US20140288149A1 (en) 2013-03-15 2014-09-25 Graham Lord Mir-142 and antagonists thereof for treating disease
RS59991B1 (sr) 2013-08-08 2020-04-30 Scripps Research Inst Metoda enzimskog in vitro obeležavanja specifičnog za položaj nukleinskih kiselina uvođenjem neprirodnih nukleotida
EP3181698A1 (en) 2015-12-16 2017-06-21 European Molecular Biology Laboratory (EMBL) Microrna mir-142 as stem cell marker
IL271903B2 (en) 2017-07-11 2025-04-01 Synthorx Inc Combination of unnatural nucleotides and methods therefor
SG11202000939PA (en) 2017-08-03 2020-02-27 Synthorx Inc Cytokine conjugates for the treatment of proliferative and infectious diseases
CN111566212A (zh) 2017-11-03 2020-08-21 因特尔纳技术有限公司 miRNA分子，等同物，安塔够妙或其来源用于治疗和/或诊断与神经元缺陷相关的病症和/或疾病或用于神经元生成和/或再生
JP2021513508A (ja) 2018-02-12 2021-05-27 インテアールエヌエー テクノロジーズ ビー．ヴイ．ＩｎｔｅＲＮＡ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｂ．Ｖ． 抗がんマイクロｒｎａ及びその脂質製剤
JP7379387B2 (ja) 2018-06-05 2023-11-14 エフ． ホフマン－ラ ロシュ アーゲー Ａｔｘｎ２発現を制御するためのオリゴヌクレオチド
AU2019300324A1 (en) 2018-07-13 2021-01-21 F. Hoffmann-La Roche Ag Oligonucleotides for modulating RTEL1 expression
EP4122943B1 (en) * 2018-07-31 2024-05-29 Roche Innovation Center Copenhagen A/S Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
EP3923974A4 (en) 2019-02-06 2023-02-08 Synthorx, Inc. IL-2 CONJUGATES AND METHODS OF USE THEREOF
WO2020206115A2 (en) 2019-04-03 2020-10-08 Bristol-Myers Squibb Company Angptl2 antisense oligonucleotides and uses thereof
EP4077671A1 (en) 2019-12-19 2022-10-26 F. Hoffmann-La Roche AG Use of saraf inhibitors for treating hepatitis b virus infection
CN115516091A (zh) 2019-12-19 2022-12-23 豪夫迈·罗氏有限公司 Cops3抑制剂用于治疗乙型肝炎病毒感染的用途
EP4077667A1 (en) 2019-12-19 2022-10-26 F. Hoffmann-La Roche AG Use of sept9 inhibitors for treating hepatitis b virus infection
WO2021122869A1 (en) 2019-12-19 2021-06-24 F. Hoffmann-La Roche Ag Use of scamp3 inhibitors for treating hepatitis b virus infection
CN114829601A (zh) 2019-12-19 2022-07-29 豪夫迈·罗氏有限公司 Sbds抑制剂用于治疗乙型肝炎病毒感染的用途
WO2021130266A1 (en) 2019-12-24 2021-07-01 F. Hoffmann-La Roche Ag Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
EP4081217A1 (en) 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
CN115605592A (zh) 2020-05-11 2023-01-13 基因泰克公司（Us） 用于治疗神经系统疾病的补体组分c1r抑制剂以及相关的组合物、系统和使用它们的方法
WO2021231211A1 (en) 2020-05-11 2021-11-18 Genentech, Inc. Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
EP4150084A1 (en) 2020-05-11 2023-03-22 Genentech, Inc. Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same
EP4200419A2 (en) 2020-08-21 2023-06-28 F. Hoffmann-La Roche AG Use of a1cf inhibitors for treating hepatitis b virus infection
AU2022384619A1 (en) 2021-11-11 2024-04-11 F. Hoffmann-La Roche Ag Pharmaceutical combinations for treatment of hbv
JP2024546993A (ja) 2021-12-17 2024-12-26 エフ． ホフマン－ラ ロシュ アーゲー Ｒｔｅｌ１及びｆｕｂｐ１を調節するためのオリゴヌクレオチドの組み合わせ
US20250340934A1 (en) * 2024-05-06 2025-11-06 Gt Molecular, Inc. Selective blocking to detect and amplify low abundant template

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008518608A (ja) * 2004-11-09 2008-06-05 サンタリス ファーマ アー／エス ＨＩＦ−１ａ発現阻害のための強力なＬＮＡオリゴヌクレオチド

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US20020068709A1 (en) * 1999-12-23 2002-06-06 Henrik Orum Therapeutic uses of LNA-modified oligonucleotides
WO2003070918A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
WO2002081628A2 (en) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
DK2796553T3 (da) * 2000-03-30 2019-09-30 Whitehead Inst Biomedical Res Rna-sekvensspecifikke formidlere af rna-interferens
CZ302719B6 (cs) * 2000-12-01 2011-09-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
EP2455467B1 (en) * 2002-02-01 2016-10-05 Life Technologies Corporation Double-stranded oligonucleotides
DK1527176T4 (en) * 2002-08-05 2017-07-03 Silence Therapeutics Gmbh ADDITIONAL NEW FORMS OF INTERFERRING RNA MOLECULES
EP1606406B2 (en) * 2003-03-21 2013-11-27 Santaris Pharma A/S SHORT INTERFERING RNA (siRNA) ANALOGUES
DK1713912T3 (da) * 2004-01-30 2013-12-16 Santaris Pharma As Modificerede Korte Interfererende RNA (Modificerede siRNA)
DK2002004T3 (en) * 2006-03-23 2015-11-30 Roche Innovation Ct Copenhagen As LITTLE INTERNAL SEGMENTED INTERFERENCE RNA

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008518608A (ja) * 2004-11-09 2008-06-05 サンタリス ファーマ アー／エス ＨＩＦ−１ａ発現阻害のための強力なＬＮＡオリゴヌクレオチド

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6012025542; Ｂｉｏｃｈｅｍｉｓｔｒｙ Ｖｏｌ．４２, 2003, ｐ．７９６７-７９７５ *
JPN6012025544; Ｂｉｏｏｒｇ．　Ｍｅｄ．　Ｃｈｅｍ．　Ｌｅｔｔ． Ｖｏｌ．８, 1998, ｐ．２２１９-２２２２ *
JPN6012025546; Ｎｕｃｌｅｉｃ　Ａｃｉｄｓ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．３１，　Ｎｏ．２１, 2003, ｐ．６３６５-６３７２ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018504380A (ja) * 2014-12-18 2018-02-15 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｒｅｖｅｒｓｉｒ（商標）化合物
JP2023018065A (ja) * 2014-12-18 2023-02-07 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｒｅｖｅｒｓｉｒ（商標）化合物
JP2024037841A (ja) * 2014-12-18 2024-03-19 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｒｅｖｅｒｓｉｒ（商標）化合物
US12241064B2 (en) 2014-12-18 2025-03-04 Alnylam Pharmaceuticals, Inc. REVERSIR™ compounds

Also Published As

Publication number Publication date
EP1984382A2 (en) 2008-10-29
CA2638837A1 (en) 2007-08-02
DK1984382T3 (da) 2012-09-03
US20090176977A1 (en) 2009-07-09
EP1984382B1 (en) 2012-08-15
WO2007085485A2 (en) 2007-08-02
WO2007085485A3 (en) 2007-09-13
AU2007209481B2 (en) 2012-01-12
AU2007209481A1 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
EP1984382B1 (en) Lna modified phosphorothiolated oligonucleotides
ES2569558T3 (es) Composición farmacéutica que comprende oligonucleótidos antisentido anti-ARNmi
EP1713912B1 (en) Modified short interfering rna (modified sirna)
CN106795200B (zh) Galnac亚磷酰胺、其核酸缀合物及其用途
CN101821277B (zh) 四氢吡喃核酸类似物
EP2970968B1 (en) Bridged bicyclic nucleosides
RU2740501C2 (ru) МОДИФИЦИРОВАННЫЕ ОЛИГОНУКЛЕОТИДЫ, АКТИВИРУЮЩИЕ РНКазу Н
WO2011115818A1 (en) 5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2635681A1 (en) Base modified oligonucleotides
EP3459962A1 (en) Tricyclic nucleosides and oligomeric compounds prepared therefrom
KR20250140080A (ko) 세포 프로그램된 사멸-리간드 1 유전자 발현을 억제하기 위한 siRNA, 이의 접합체 및 약학적 조성물과 용도
CN111448316A (zh) 新的硫代亚磷酰胺
CN119285688A (zh) 修饰的核苷酸单体及其用途
CN118813612A (zh) 一种化合物在RNAi药物中的应用
CA3130431A1 (en) Phosphonoacetate gapmer oligonucleotides
CN111757936A (zh) 包含二硫代磷酸酯核苷间连接的寡核苷酸
WO2025148770A1 (zh) 修饰的核苷酸单体及其用途
JP2025529338A (ja) 炭素環ヌクレオシド、オリゴヌクレオチド及びその製造方法並びに医薬用途
WO2025188589A1 (en) NOVEL NUCLEOTIDES AND OLIGONUCLEOTIDES AND RNAi AGENTS COMPRISING THE SAME
WO2023167094A1 (ja) ５'位修飾ヌクレオシドおよびそれを用いたヌクレオチド
CN113474352A (zh) 新型亚磷酰胺
HK40060207A (en) Novel phosphoramidites
WO2021166981A1 (ja) 架橋型ヌクレオシドおよびそれを用いたヌクレオチド
HK40060208A (en) Phosphonoacetate gapmer oligonucleotides
HK1237788A1 (en) Galnac phosphoramidites, nucleic acid conjugates thereof and their use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120816

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121009